125 related articles for article (PubMed ID: 10638040)
1. A pharmacoeconomic evaluation of major depressive disorder (Italy).
Casciano J; Arikian S; Tarride JE; Doyle JJ; Casciano R
Epidemiol Psichiatr Soc; 1999; 8(3):220-31. PubMed ID: 10638040
[TBL] [Abstract][Full Text] [Related]
2. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom.
Freeman H; Arikian S; Lenox-Smith A
Pharmacoeconomics; 2000 Aug; 18(2):143-8. PubMed ID: 11067648
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
Einarson TR; Addis A; Iskedjian M
Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder.
van Baardewijk M; Vis PM; Einarson TR
Curr Med Res Opin; 2005 Aug; 21(8):1271-9. PubMed ID: 16083537
[TBL] [Abstract][Full Text] [Related]
6. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials.
Machado M; Iskedjian M; Ruiz I; Einarson TR
Curr Med Res Opin; 2006 Sep; 22(9):1825-37. PubMed ID: 16968586
[TBL] [Abstract][Full Text] [Related]
7. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
Shelton RC; Haman KL; Rapaport MH; Kiev A; Smith WT; Hirschfeld RM; Lydiard RB; Zajecka JM; Dunner DL
J Clin Psychiatry; 2006 Nov; 67(11):1674-81. PubMed ID: 17196045
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK.
Lenox-Smith A; Conway P; Knight C
Pharmacoeconomics; 2004; 22(5):311-9. PubMed ID: 15061681
[TBL] [Abstract][Full Text] [Related]
10. Bupropion: a review of its use in the management of major depressive disorder.
Dhillon S; Yang LP; Curran MP
Drugs; 2008; 68(5):653-89. PubMed ID: 18370448
[TBL] [Abstract][Full Text] [Related]
11. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
[TBL] [Abstract][Full Text] [Related]
12. The health economic impact of antidepressant usage from a payer's perspective: a multinational study.
Casciano J; Doyle J; Arikian S; Casciano R
Int J Clin Pract; 2001 Jun; 55(5):292-9. PubMed ID: 11452675
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder.
Nordström G; Danchenko N; Despiegel N; Marteau F
Value Health; 2012; 15(2):231-9. PubMed ID: 22433753
[TBL] [Abstract][Full Text] [Related]
14. C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy.
Mencacci C; Aguglia E; Biggio G; Cappellari L; Di Sciascio G; Fagiolini A; Maina G; Tortorella A; Katz P; Ripellino C
Adv Ther; 2013 Jul; 30(7):697-712. PubMed ID: 23929174
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
Ye W; Zhao Y; Robinson RL; Swindle RW
BMC Psychiatry; 2011 Jan; 11():19. PubMed ID: 21281479
[TBL] [Abstract][Full Text] [Related]
16. Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder.
Fagiolini A; Cardoner N; Pirildar S; Ittsakul P; Ng B; Duailibi K; El Hindy N
Expert Opin Pharmacother; 2023; 24(15):1715-1723. PubMed ID: 37501324
[TBL] [Abstract][Full Text] [Related]
17. Spotlight on bupropion in major depressive disorder.
Dhillon S; Yang LP; Curran MP
CNS Drugs; 2008; 22(7):613-7. PubMed ID: 18547129
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
Choi SE; Brignone M; Cho SJ; Jeon HJ; Jung R; Campbell R; Francois C; Milea D
Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
[TBL] [Abstract][Full Text] [Related]
19. Escitalopram: a review of its use in the management of major depressive disorder.
Murdoch D; Keam SJ
Drugs; 2005; 65(16):2379-404. PubMed ID: 16266205
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
Soini E; Hallinen T; Brignone M; Campbell R; Diamand F; Cure S; Aalto-Setälä M; Danchenko N; Koponen H; Kolasa K
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):293-302. PubMed ID: 27680105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
